Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer patients may soon get immunotherapy as a quick shot

NCT ID NCT06212752

Ongoing Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a subcutaneous (under-the-skin) injection of pembrolizumab works as well as the standard IV infusion for people with metastatic non-small cell lung cancer. About 39 Japanese adults will receive either the shot or the IV, both combined with chemotherapy. The main goal is to compare drug levels in the blood and check safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

pembrolizumab with hyaluronidase (subcutaneous injection)

What this could lead to

If it works, this could offer a more convenient, faster way to receive immunotherapy for lung cancer, potentially replacing lengthy IV infusions.

What could go wrong

This is a small, early-phase study in Japanese patients only, so results may not apply broadly. The main goal is to compare drug levels, not yet to prove better outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC NON SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC NON SMALL CELL LUNG CANCER

Contacts and locations

Locations

  • Fujita Health University ( Site 4406)

    Toyoake, Aichi-ken, 470-1192, Japan

  • Gunma Prefectural Cancer Center ( Site 4416)

    Otashi, Gunma, 373-8550, Japan

  • Juntendo University Hospital ( Site 4413)

    Bunkyo-ku, Tokyo, 1138431, Japan

  • Kanagawa Cardiovascular and Respiratory Center ( Site 4404)

    Yokohama, Kanagawa, 236-0051, Japan

  • Kansai Medical University Hospital ( Site 4408)

    Hirakata, Osaka, 573-1191, Japan

  • Kurashiki Central Hospital ( Site 4409)

    Kurashiki, Okayama-ken, 710-8602, Japan

  • Kurume University Hospital ( Site 4412)

    Kurume, Fukuoka, 830-0011, Japan

  • Miyagi Cancer Center ( Site 4401)

    Natori-shi, Miyagi, 981-1293, Japan

  • National Hospital Organization Hokkaido Cancer Center ( Site 4415)

    Sapporo, Hokkaido, 003-0804, Japan

  • National Hospital Organization Kyushu Cancer Center ( Site 4410)

    Fukuoka, 811-1395, Japan

  • National Hospital Organization Kyushu Medical Center ( Site 4411)

    Fukuoka, 810-8563, Japan

  • Nippon Medical School Hospital ( Site 4403)

    Tokyo, 113-8603, Japan

  • Osaka International Cancer Institute ( Site 4407)

    Osaka, 541-8567, Japan

  • Osaka Medical and Pharmaceutical University Hospital ( Site 4414)

    Takatsuki, Osaka, 569-8686, Japan

  • Saitama Prefectural Cancer Center ( Site 4402)

    Ina-machi, Saitama, 362-0806, Japan

  • Sendai Kousei Hospital ( Site 4400)

    Sendai, Miyagi, 9800873, Japan

  • Shizuoka Cancer Center ( Site 4405)

    Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777, Japan

  • Tochigi Cancer Center ( Site 4417)

    Utsunomiya, Tochigi, 320-0834, Japan